 Patent Application Title |
Patent App Num. |
Date |
| Use of aerogels for preparing a material for thermal insulation | 20120097884 | 20120426 |
| in which R represents a side chain of an amino acid, R1 represents a (C1-C8)alkyl, (C1-C8)alkoxy, aryl, aryloxy, or glycoside group, n=1 or 2 and A represents an aromatic group with one or more rings.
... |
| Anisic acid modified steviol glycoside sweetened beverage products | 20120088013 | 20120412 |
| Taste of a non-nutritive steviol glycoside sweetener is improved by using anisic acid in an amount sufficient to mask the metallic aftertaste of the non-nutritive steviol glycoside sweetener when the sweetener is contained in a beverage, beverage concentrate or syrup, or reduced calorie sweetener.
... |
| Stevia plant named 'akh l1 ' | 20120090062 | 20120412 |
| A new and distinct cultivar of stevia plant named ‘AKH L1’, characterized by its combination of late cycle, light green or yellow green leaves, high number of nodes on the main stem, medium number of basal buds, high Rebaudiosido A of total Glycoside Steviol content, and high yielding of dried leaves at harvest.
... |
| Stevia plant named ' akh l4 ' | 20120090063 | 20120412 |
| A new and distinct cultivar of stevia plant named ‘AKH L4’, characterized by its combination of early cycle, dark green leaves, medium number of nodes on the main stem, high number of basal buds, high Rebaudioside A of total Glycoside Steviol content, and high yielding of dried leaves at harvest.
... |
| Use of glycoside hydrolase 61 family proteins in processing of cellulose | 20120083019 | 20120405 |
| The invention provides recombinant GH61 proteins obtained from Myceliophtora thermophila, and nucleic acids that encode such proteins. The invention also provides protein fractions isolated from M. thermophila supernatant that have GH61 protein activity. These preparations can be used to increase yield of products from reactions in which a cellulose-containing substrate undergoes saccharification by one or more cellulase enzymes, such as endoglucanase, β-glucosidase, or cellobiohydrolase. Combinations of GH61 protein and cellulases can be used to break down cellulosic biomass into fermentable sugars in the production of ethanol.
... |
Subscribe to updates on this page: Glycoside RSS  |
| Agent for inhibiting peritoneal membrane thickening | 20120083461 | 20120405 |
| (in this regard, however, R1, R2, R3, and R4 each represent a hydrogen atom or a lower alkyl group which may be the same as or different from each other; R5 represents a hydrogen atom, a lower alkyl group or a lower acyl group; X represents a mono-sugar residue or an oligo-sugar residue in which a hydrogen atom of hydroxyl group in sugar residue may be substituted by a lower alkyl group or a lower acyl group; n is an integer of 0 to 6; and m is an integer of 1 to 6), or a dialysis fluid comprising the same.
... |
| Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | 20120039828 | 20120216 |
| The composition comprises of a component A selected from a hydroxylated derivative of benzoic acid or of cinamic acid, their esters, amides or salts, a glycoside of a hexose, and their mixtures; and a component B selected from quinic acid, shikimic acid, their alkaline metal or alkaline earth salts, their methyl esters, and mixtures of the same. This composition is suitable for protecting the skin against ultraviolet radiation coming from the sun or artificial sources, such as those used in phototherapy units and in sun tanning rooms. For application in the field of dermatology and nutrition, and, in particular, in the photoprotection of the skin and mucosa, photo-ageing and photocarcinogenesis, including protection of the immune system associated with the skin.
... |
| Agricultural pesticide compositions | 20120040833 | 20120216 |
| A pesticide composition contains, based on 100 parts by weight (“pbw”) of the composition: (a) from about 15 to about 65 pbw of one or more pesticide compounds, (b) from greater than 0 to about 10 pbw of one or more fatty acid (C1-C3) esters, and (c) optionally, up to about 20 pbw of one or more surfactants, wherein the surfactant component typically comprises: (i) one or more betaine surfactants, (ii) one or more glycoside surfactants, (iii) one or more amine oxide surfactants, (iv) one or more fatty (ether) amine alkoxylate surfactants, or (v) a surfactant mixture comprising at least one surfactant from each of at least two of the surfactant categories (i), (ii), (iii), and (iv). A method for controlling a target pest, includes the... |
| Enzymatic production of an ethylenically unsaturated glycoside using polysaccharides | 20120028307 | 20120202 |
| in the presence of a glycosidase, such as an amylase, cellulase, glucosidase or and galactosidase, or a glycosyltransferase, such a cyclomaltodextrin glucanotransferase.
... |
| Compositions for drug administration | 20120021980 | 20120126 |
| The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of glucagon-like peptide-1 analogs, such as exenatide, albiglutide, taspoglutide, liraglutide and lixisenatide.
... |
| Enzymatic removal of steryl glycosides in fatty acid alkyl esters | 20120009659 | 20120112 |
| The present invention relates to a process of reducing the content of steryl glycoside in a bio-diesel composition which comprises a step of contacting the composition with an enzyme being capable of acylating the steryl glycoside.
... |
| Digoxin-like fungal glycoside with cytotoxic properties: novel assay and applications | 20120003261 | 20120105 |
| The present invention provides methods of isolating cytotoxic metabolites from a fungus, and specific metabolites obtained from such methods. The present invention also provides methods of controlling fungal diseases in plants by treating the plants with cytotoxic metabolites as well as methods of treating cardiac arrhythmia in organisms in need of such treatment by administering the above-noted metabolites to such organisms.
... |
| Glycoside compounds and pharmaceutical compositions thereof | 20110319350 | 20111229 |
| The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.
... |
Subscribe to updates on this page: Glycoside RSS |
| Cleaning composition for treating tissue for transplantation derived from human/animal | 20110312917 | 20111222 |
| The present invention relates to a cleaning composition for removing cellular components from tissue for transplantation derived from humans and animals. More particularly, the present invention relates to a cleaning composition for treating tissue for transplantation comprising a polyoxyethyleneglycol C14-C20alkyl ether as a first protein solubilizing component, a C6-C8alkylphenol polyethoxylate as a first lipid solubilizing component, a C10-C16alkyl glycoside as a second protein solubilizing component and a C9-C12 alkylphenoxy polyethoxy ethanol as a second lipid solubilizing component.
... |
| Triterpene saponins, methods of synthesis, and uses thereof | 20110300177 | 20111208 |
| The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
... |
| Cleaning agents for wellbore cleaning and methods of use thereof | 20110272160 | 20111110 |
| A method of cleaning walls of a wellbore that includes contacting the walls with a cleaning fluid, the cleaning fluid comprising: a base fluid comprising a blend of a base oil and at least one of a mutual solvent or a terpene; and an alkyl glycoside is disclosed herein.
... |
| Environmentally acceptable acidic lavatory treatment compositions | 20110269659 | 20111103 |
| Aqueous, thickened, acidic compositions which exhibit a pH of about 7 or less preferably 5 or less, and comprise an organic acid constituent selected from formic acid, citric acid and oxalic acid, a thickening constituent or constituents based on one or more gums, particularly xanthan gum which form a thickener system in the inventive composition, and at least one detersive surfactant based on glycoside surfactants, water in an amount of at least 85% wt., preferably at least about 90% wt., and one or more further optional constituents, wherein the compositions exclude: (a) surfactant compounds which include a nitrogen atom in the surfactant compound, and (b) inorganic acids.
... |
| Composition comprising a glycoside of a mono- or diacylglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition | 20110257110 | 20111020 |
| A composition and use of a composition comprising a glycoside of a mono- or diacylglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, e.g. fish oil. The composition may also comprise a rose hip concentrate. The composition is used to treat inflammatory diseases, e.g. joint diseases such as osteoarthritis, or joint pain and stiffness. By administering the composition on a daily basis, a significant reduction in joint pain and stiffness of the affected joints is achieved, which allows individuals suffering from especially joint diseases to resume daily activities.
... |
| Compositions for drug administration | 20110257096 | 20111020 |
| The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery of peptides containing non-naturally occurring structures including D-amino acids and/or chain cyclization.
... |
| Method to make steviol glycoside isomers | 20110251381 | 20111013 |
| wherein R1 may be hydrogen, 1-β-D-glucopyranosyl, or 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, and R2 may be hydrogen, 1-β-D-glucopyranosyl, 2-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2,3-bis(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-1-β-D-glucopyranosyl, 2-(1-α-L-rhamnopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl, or 2-(1-β-D-xylopyranosyl)-3-(1-β-D-glucopyranosyl)-1-β-D-glucopyranosyl. Methods for making steviol glycoside isomers are also disclosed. These compounds may be present in food and beverage products as non-nutritive sweeteners.
... |
| Treatment of hyperproliferative disorders using cardiac glycosides | 20110250297 | 20111013 |
| Provided are methods and compositions for treating and preventing hyperproliferative disorders such as psoriasis by administration of a cardiac glycoside alone or in combination locally or systemically with a calciotropic agents and/or a diffusion-limiting component, such a vasoconstrictor or collagen barrier.
... |
| Pregnane glycoside compositions and caralluma extract products and uses thereof | 20110236510 | 20110929 |
| Pregnane glycoside or a Caralluma extract including the pregnane glycoside of the present invention can be used for medical purposes and as food additives, such as a treatment of obesity, a reduction of blood glucose, a reduction of blood pressure, a reduction in hip, waist and arm circumferences, a reduction of fat, increase of BMR, a decrease of BMI, an increase of lean body mass, an appetite-suppression and a reduction/elimination of joint pain, anti-aging, a treatment for falling sex drive, the treatment for impotency and an erectile dysfunction, and an enhancement of energy levels.
... |
| Smoking article including alkanoylated glycoside and method of making | 20110232655 | 20110929 |
| A smoking composition for inclusion in a combustible smoking article includes a combustible organic material, such as tobacco and/or tobacco substitutes and at least one alkanoylated glycoside for enhancing the flavor of mainstream smoke. Optionally, dry hops extract can also be included in the smoking composition.
... |
| Linkable lewis x analogs | 20110229409 | 20110922 |
| Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand con-jugatcs by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.
... |
| Process for manufacturing a sweetener and use thereof | 20110195169 | 20110811 |
| Highly purified Stevioside, Rebaudioside A and a purified sweet steviol glycoside mixture were prepared from sweet glycoside extracts obtained from Stevia rebaudiana Bertoni leaves. The resulting sweeteners are suitable as non-calorie, non-cariogenic, non-bitter, non-lingering sweeteners, which may be advantageously applied in foods, beverages, and milk products.
... |
| Solubility enhanced terpene glycoside(s) | 20110195161 | 20110811 |
| Disclosed herein are inclusion complexes comprising a substantially pure terpene glycoside and at least one cyclodextrin, wherein the solubility of the inclusion complex is greater than the solubility of the substantially pure terpene glycoside alone. Also disclosed herein are beverage compositions comprising at least one inclusion complex. Further disclosed herein are methods of increasing the solubility of a substantially pure terpene glycoside, comprising combining a substantially pure terpene glycoside with at least one cyclodextrin to form at least one inclusion complex. Still further disclosed herein are methods for improving the taste of an orally ingestible composition and an inclusion complex comprising at least two substantially pure terpene glycoside and at least one cyclodextrin.
... |
| Microorganism-capturing compositions and methods | 20110183398 | 20110728 |
| The invention relates to compositions, methods, devices, and kits for non-specifically isolating bacterial cells. The compositions comprise a solid support which has a surface comprising a combination of a carbohydrate and a biotin-binding protein, wherein the protein is covalently bonded to the carbohydrate, and wherein the protein is linked to the solid support via the carbohydrate; and at least one of 1) a plurality of bacterial cells non-specifically bound to the combination of the carbohydrate and the protein or 2) an amphiphilic glycoside of a steroid or triterpene. The methods, devices, and kits include at least one of these compositions.
... |
| New steviol glycoside | 20110183056 | 20110728 |
| Nobel Stevia Sweetening components are provided. Through the analysis of the components of the nobel Steviol Glycoside included in the stevia extract and/or crystals, not only the quality control of sweeteners, but judgment on the correctness of indication of origin or infringement of right are facilitated since the raw material of the sweetener can be identified.
... |
| Methods for the electrolytic production of xylo-pent-1,5-diose | 20110180418 | 20110728 |
| Method and electrochemical cells for producing xylo-pent-1,5-diose are provided. The xylo-pent-1,5-diose may be formed in a solution initially comprising D-glucuronic acid or D-glucuronic acid glycoside. The xylo-pent-1,5-diose may be formed by electrochemical oxidative decarboxylation of the D-glucuronic acid or D-glucuronic acid glycoside in the solution in the presence of a graphite foil electrode with improved current efficiency and/or current density.
... |
| Method | 20110173876 | 20110721 |
| The present invention relates to a method for reducing the amount of steryl glycoside in an oil or fat (e.g. a biofuel substrate) and/or a biofuel, the method comprising admixing one or more enzymes with an oil or fat comprising steryl glycoside; such that said one or more enzymes degrades the steryl glycoside. The one or more enzymes is preferably an enzyme which is capable of hydrolysing the glycosidic bond in a steryl glycoside. Suitably the enzyme may be a glycosidase enzyme and/or a β-glucosidase and/or an amyloglucosidase.
... |
| Agricultural adjuvant compositions, pesticide compositions, and methods for using such compositions | 20110015071 | 20110120 |
| An adjuvant composition contains an adjuvant composition, comprising, based on 100 parts by weight of the composition: (a) from about 10 to 100 parts by weight of a combined of one or more betaine surfactants and one or more glycoside surfactants, comprising, based on 100 parts by weight of the combined amount: (i) from greater than 0 to less than 100 parts by weight of the one or more betaine surfactants, and (ii) from greater than 0 to less than 100 parts by weight of one or more glycoside surfactants, and (b) from 0 to about 90 parts by weight water A pesticide composition contains based on 100 parts by weight of the composition: (a) from greater than 0 parts by weight to about 20 parts... |
| Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics | 20110005518 | 20110113 |
| A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.
... |
| Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia | 20110003762 | 20110106 |
| A process of enhancing insulin excretion in a subject includes administering to the subject a polyphenol active ingredient. The polyphenol active ingredient is a purified cyanidin-3-glycoside alone or purified cyanidin alone. The pharmaceutically acceptable carrier is administered with the polyphenol active ingredient.
... |
| Cyclic carbonyl monomers functionalized with carbohydrates, polymers derived therefrom, and methods of preparation thereof | 20100317838 | 20101216 |
| wherein at least one W′ or Wa group comprises a protected glycoside; each Z independently represents O, S, NH or NW″; n is an integer from 0 to 6 wherein when n is 0, carbons labeled 4 and 6 are linked together by a single bond; each W′ and Wa group independently represents a hydrogen, a halide, an alkyl group comprising 1 to 20 carbons, an ester group comprising 1 to 20 carbons, an amide group, an aryl group comprising 1 to 20 carbons, an alkoxy group comprising 1 to 20 carbons, or a foregoing W′ or Wa group substituted with a protected glycoside; and each W″ group independently represents an alkyl group comprising 1 to 20 carbons, an aryl group comprising 1 to 20 carbons,... |
| Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside | 20100317541 | 20101216 |
| A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising... |
| Compositions containing sesamin-class compound(s) and quercetin glycoside(s) | 20100311676 | 20101209 |
| The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced.
... |
| Whitening agent comprising equol or its saccharide derivative as an effective ingredient | 20100280231 | 20101104 |
| An object of the present invention is to provide a whitening agent containing a novel whitening substance as an effective ingredient. The above object is attained by providing a whitening agent containing equol and/or equol glycoside, in which one or more glycosyl groups bind to the hydroxyl group(s) of equol, as an effective ingredient.
... |
| Wax-in-water emulsion comprising a combination of a glutamic acid derivative and an alkylpolyglycoside | 20100278770 | 20101104 |
| The present invention relates to a composition for coating keratin fibres, more particularly the eyelashes, characterized in that it is present in the form of a wax-in-water emulsion comprising a combination of at least one glutamic acid derivative and/or salt thereof and at least one alkylpolyglycoside.
... |
| Compositions comprising siraitia grosvenori extracts and methods for the treatment of infection | 20100272838 | 20101028 |
| A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of Siraitia grosvenori Swingle and administering the composition to the subject. The fruit from which the extract is derived is Luo Han Guo. The extract comprises at least one thterpene glycoside, which may be in the form of a mogroside compound. The extract has been shown to be effective in the treatment of viral infections such as hepatitis C and HIV. Also provided are pharmaceutical compositions comprising at least one thterpene glycoside, or an analogue, metabolite, precursor, derivative, pharmaceutically active salt or pro-drug thereof.
... |
| Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | 20100261664 | 20101014 |
| in which the radicals have the stated meanings, and their physiologically tolerated salts and processes for their preparation. The compounds are suitable for example as antidiabetics.
... |
| Triazole-based aminoglycoside-peptide conjugates and methods of use | 20100261639 | 20101014 |
| Aminoglycoside-amino acid and -peptide conjugates comprising a triazolyl linker are provided along with efficient methods of their preparation. The aminoglycoside may be an aminoglycoside antibiotic. Conjugates comprising an aminoglycoside antibiotic may exhibit antimicrobial activities against Gram-positive and/or Gram-negative strains and display significantly enhanced activity against multi-drug resistant MRSA and MRSE when compared to their unconjugated aminoglycoside antibiotic counterparts.
... |
| Method for glycosylation of flavonoid compounds | 20100256345 | 20101007 |
| The present invention provides a method for preparing a glycoside of a flavonoid compound, which comprises the step of treating flavonoid and a glycosyl donor with an enzymatic agent having glycosylation activity and being derived from the genus Trichoderma (preferably Trichoderma viride or Trichoderma reesei). Such a flavonoid compound includes a catechin compound or a methylated derivative thereof, and the glycosyl donor includes a carbohydrate containing a maltotriose residue (preferably maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose, dextrin, γ-cyclodextrin or soluble starch). Glycosides obtained by the present invention have higher water solubility, improved taste, and increased stability. The present invention also provides novel glycosides of catechin compounds, which are obtained by the method of the present invention.
... |
| Neoglycorandomization and digitoxin analogs | 20100256078 | 20101007 |
| The present invention provides methods of producing libraries of compounds with enhanced desirable properties and diminished side effects as well as the compounds produced by the methods. In preferred embodiments, methods of the present invention use a universal chemical glycosylation method that employs reducing sugars and requires no protection or activation. In a preferred embodiment, the invention provides a library of neoglycoside digitoxin analogs that includes compounds with significantly enhanced cytotoxic potency toward human cancer cells and tumor-specificity, but are less potent Na+/K+-ATPase inhibitors in a human cell line than digitoxin.
... |
| Process for manufacturing a sweetener and use thereof | 20100255171 | 20101007 |
| Highly purified Stevioside, Rebaudioside A and a purified sweet steviol glycoside mixture were prepared from sweet glycoside extracts obtained from Stevia rebaudiana Bertoni leaves. The resulting sweeteners are suitable as non-calorie, non-cariogenic, non-bitter, non-lingering sweeteners, which may be advantageously applied in foods, beverages, and milk products.
... |
| Epothilone glycoside and use thereof | 20100249050 | 20100930 |
| and a pharmaceutical composition having the epothilone glycoside and a pharmaceutically acceptable excipient. The epothilone glycoside or the pharmaceutical composition having the epothilone glycoside can prevent or treat cancers such as liver cancer, lung cancer, and breast cancer.
... |
| Washing and conditioning cosmetic composition comprising four surfactants and a non-silicone | 20100249004 | 20100930 |
| The present disclosure relates to detergent cosmetic compositions for keratin fibers, for example human keratin fibers such as the hair, comprising at least one anionic surfactant (A) comprising in its structure at least one group chosen from sulfate, sulfonate and phosphate groups, at least one carboxylic alkyl ether anionic surfactant (B) other than the at least one anionic surfactant (A), at least one surfactant chosen from amphoteric and zwitterionic surfactants (C), at least one alkyl(poly)glycoside nonionic surfactant (D), at least one non-silicone fatty substance (E), and optionally at least one cationic polymer (F), wherein the weight ratio of the amount of the at least one anionic surfactant (A) to the amount of the at least one nonionic surfactant (D) has a value ranging from 0.5 to... |
| Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product | 20100247620 | 20100930 |
| This invention can produce a co-encapsulated combination drug product consisting of a topoisomerase 1 inhibitor such as camptothecins including neat camptothecin and its derivatives irinotecan, topotecan and other derivatives, and a tyrosyl-DNA phosphodiesterase (Tdp1) such as aminoglycoside antibiotics including neomycin and tetracycline, and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin.
... |
| Method for preparing finely divided emulsions | 20100247588 | 20100930 |
| Finely divided emulsions, preferably for use in cosmetic preparations can be produced by first producing a microemulsion which contains at least 10-20% by weight of an alkyl(oligo)glycoside of general formula R1O-[G]p wherein R1 represents an alkyl group and/or alkenyl group with 4 to 22 carbon atoms, G represents a sugar with 5 or 6 carbon atoms and p is a number from 1 to 10, and 4-10% of an ester of glycerol with a fatty acid having a chain length of C12-C22 and 5-30% by weight of an oil body and the remainder to 100% by weight being constituted of water and optionally other ingredients, and then diluting said microemulsion with water amounting to 5 to 20 times the volume of the microemulsion at temperatures of... |
| Emulsifying compositions based on alkyl polyglycosides and esters | 20100234320 | 20100916 |
| Emulsifying composition containing 1 to 98% of a mixture of alkyl glycosides, a mixture of alcohol esters, a mixture of alcohol esters, 1 to 90% of an alcohol and 0 to 97% of a mixture of alkyl glycoside esters.
... |
| Process for manufacturing a sweetener and use thereof | 20100227034 | 20100909 |
| Highly purified Stevioside, Rebaudioside A and a purified sweet steviol glycoside mixture were prepared from sweet glycoside extracts obtained from Stevia rebaudiana Bertoni leaves. The resulting sweeteners are suitable as non-calorie, non-cariogenic, non-bitter, non-lingering sweeteners, which may be advantageously applied in foods, beverages, and milk products.
... |
| Mouse in which genome is modified | 20100223686 | 20100902 |
| A mouse or progenies thereof in which genome is modified so as to have decreased or deleted activity of an enzyme relating to modification of a sugar chain in which the 1-position of fucose is bound to the 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked complex sugar chain.
... |
| Novel diglycosidase and gene encoding the same | 20100221810 | 20100902 |
| (7) isoelectric point (pI): about 4.3.
... |
| Polar organic extract of eurycoma longifolia | 20100221370 | 20100902 |
| The present invention provides a composition including a polar organic extract of Eurycoma longifolia and a fraction derived from the polar organic extract, said composition comprising of quassinoids, coumarins, their glycosides, analogues and derivatives, which exhibits bioactivity of increasing spermatozoa production and spermatozoa quality in terms of morphology and motility, as well as increasing testosterone synthesis and release from cells of males. The extraction method of E. longifolia plant to produce the polar organic extract, and the subsequent purification to produce the fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives, and uses for manufacturing a preparation for infertility treatment are also provided. The fraction of polar organic extract containing the quassinoids, coumarins, their glycosides, analogues and derivatives is formulated for... |
| Dehydroascorbic acid or monomeric, polymeric or isomeric derivative thereof and an amine for artificially coloring the skin | 20100221203 | 20100902 |
| b) at least one amine compound.
... |
| Method of producing nucleosides | 20100210833 | 20100819 |
| Method of producing a free nucleoside compound, the compound 2′-deoxy-5-azacytidine (Decitabine) being excluded, by reacting a glycoside donor preferably a 1-halogen derivative, or 1-O-acyl, 1-O-alkyl, or an imidate preferably a trichloromethyl derivative, or a thio-alkyl derivative of a blocked monosaccharide or oligosaccharide preferably ribose and 2-desoxyribose derivatives with a protected nucleoside base, in a suitable anhydrous solvent and in the presence of a catalyst, and removing the protecting groups from said blocked nucleoside compound, wherein said catalyst is selected from the group comprising salts of an aliphatic sulphonic acid and/or salts a strong inorganic acid containing a non-nucleophilic anion.
... |
| Stabilizing alkylglycoside compositions and methods thereof | 20100209485 | 20100819 |
| The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.
... |
| Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity | 20100204171 | 20100812 |
| Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.
... |
| Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof | 20100204169 | 20100812 |
| This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl... |
| Method for producing glycoside aglycone | 20100191003 | 20100729 |
| It is intended to provide a method for producing aglycone from a glycoside efficiently at low cost without using an acid catalyst or an organic solvent. The method for producing aglycone, characterized by bringing a glycoside into contact with high temperature high pressure water. The temperature of the high temperature high pressure water is generally from 100 to 374° C., preferably from 140 to 320° C., more preferably from 200 to 300° C. The pressure of the high temperature high pressure water may be not lower than the saturated water vapor pressure at the temperature, i.e., a pressure at which the liquid state is maintained.
... |
| Cosmetic/pharmaceutical compositions comprising hyaluronic acid and administration thereof for reducing signs of aging | 20100190742 | 20100729 |
| Cosmetic/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, at least (i) hyaluronic acid and/or one of its derivatives and (ii) a C-glycoside compound, at least one of the constituents (i) and (ii) advantageously being in a form suitable for administration by injection, and administration thereof for filling depressions on the surface of the skin and for reducing signs of aging or for re-establishing the volume of the body or face.
... |
| Stabilizing alkylglycoside compositions and methods thereof | 20090326193 | 20091231 |
| The present invention relates to alkylglycoside-containing compositions and methods for preventing loss of a parathyroid hormone (PTH) analog or octreotide via denaturation due to adherence upon contact with glass.
... |
| Use of galactose c-glycoside derivatives as protective agent and/or gama delta t lymphocyte activator | 20090325890 | 20091231 |
| The composition will find applications for promoting skin tissue repair, for reequilibrating epidermal proliferation and differentiation disorders which appear with lack of sleep, and for improving the appearance of the head of hair and limiting hair loss.
... |
| Stable c-glycoside sugar and c-glycoconjugate mimetics, method for preparing same and uses thereof in particular in cosmetics and drugs | 20090318678 | 20091224 |
| The invention concerns a C-glycoside compound of formula (I); wherein: n is equal to 1 or 2; Y represents H or halogen; X is an alkyl chain bearing at least one amino, amide, acid, ester, carbonyl, alcohol, aryl function or a carbonyl, ester amide, amino, alcohol group; the R's, identical or different, represent a OH or OR′ group where R′ is an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl, tertiobutyldiphenylsilyl group or one or more sugars; R1 represents OR′, NR″R″′, N3, or a phthalamide with R″ and R″′, identical or different, represent H or an alkyl, aryl, benzyl, benzoyl, acetyl, alkoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl group; R2 represents H or halogen or a OH, OR, NR″R″′ or N3 group, as well as derivatives thereof in physiologically or pharmaceutically acceptable... |
| Novel gem-difluorinated c-glycoside compounds derived from podophyllotoxin, their preparation and their applications | 20090318675 | 20091224 |
| The invention relates to a gem-difluoride glycoconjugated compound with formula (I): where R represents II or a benzyl, acetyl, benzoyl alkyl group, R1 and R2 may be identical or different and represent H or an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl, tertiobutyldiphenylsilyl protective group or an acetal group of the CR′R′ type, where R′ and R′ may be identical or different and represent H or an alkyl, aryl, benzyl or thiophene group, R3 represents H or an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl or tertiobutyldiphenylsilyl protective group, R4 represents OR″, NGR′GR′, N3, or a phthalimide, where R″ represents H or an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl or tertiobutyldiphenylsilyl protective group, GR′ and GR′ may be identical or different and represent II or an alkyl, benzyl,... |
| High throughput screening method of binding inhibitor between caspase3 and xiap and binding inhibitor screened thereby | 20090318376 | 20091224 |
| The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy.... |
| Equal-containing fermentation product of soybean embryonic axis, and method for production thereof | 20090311353 | 20091217 |
| The equol-containing fermented soybean hypocotyl material of the invention is obtained by fermenting soybean hypocotyls using at least one microorganism having an equol-producing ability by utilizing at least one daidzein compound selected from the group consisting of diadzein glycosides, daidzein, and dihydrodaidzein.
... |
| Use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, and compositions containing it | 20090306011 | 20091210 |
| The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition.
... |
| Use of a galactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity | 20090305997 | 20091210 |
| The present invention relates to a novel galactose derivatives of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.
... |
| Stabilizing alkylglycoside compositions and methods thereof | 20090305958 | 20091210 |
| The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
... |
| Supercooling promoting agent | 20090302265 | 20091210 |
| The supercooling ability of identified flavonoid glycoside and synthesized flavonoid glycoside with similar structure was tested. It was found that the supercooling promoting agent comprising these flavonoid glycosides enables to stably supercool bulk water at low temperature for long-term. The aqueous solution containing the supercooling promoting agent of the present invention is useful to store biological materials at low temperature.
... |
| Use of alkylpolyglycosides as emulsifying agents for the preparation of oil-in-water emulsions comprising inorganic fillers or pigments, and oil-in-water emulsions comprising such alkylpolyglycosides | 20090291052 | 20091126 |
| A composition and process of preparation of emulsifier agents based on an alkylpolyglycoside structure with a length of alkyl chain having from 6 to 12 carbon atoms to be used. The resulting emulsions exhibit an excellent dispersion of the fillers and/or pigments without it being necessary to add coemulsifier or dispersant. The emulsifier makes it possible, by itself alone, to prevent the reagglomeration of the fillers and/or pigments.
... |
| Cynara scolymus extracts, the use thereof and formulations containing them | 20090285911 | 20091119 |
| The present invention relates to the preparation of a Cynara scolymus extract obtainable by fractioning on a resin. The process of the invention allows to obtain an extract, starting from the aerial parts of the plant Cynara scolymus, containing three classes of active principles, namely dicaffeoylquinic acids, luteolin and cynaropicrin glycosides, in a constant ratio. Cynaropicrin is stabilized by addition of precise amounts of sulfated amino acids or suitable thio-derivatives. These extracts have hypolipemizing, anti-dyspeptic and vascular anti-inflammatory activities. The extracts are mainly formulated in Enothera biennis oil or in oils rich in ω-3 and ω-6 acids which enhance the vascular activity.
... |
| Systemic mitigation of environmental stress on plants and the fruit thereof | 20090280985 | 20091112 |
| Systemic mitigation of the heat stress damage to plants and pre-harvest fruit caused by environmental stress on the plant and fruit is realized by applying to the root zone of the plant a bioefficaciously effective amount of a composition selected from the group consisting of ethylene oxide-propylene oxide block copolymer, alkyl ethers of ethylene oxide-propylene oxide block copolymer, alkyl polyglycoside, and combinations thereof.
... |
| Systemic mitigation of environmental stress on plants and the fruit thereof | 20090280985 | 20091112 |
| Systemic mitigation of the heat stress damage to plants and pre-harvest fruit caused by environmental stress on the plant and fruit is realized by applying to the root zone of the plant a bioefficaciously effective amount of a composition selected from the group consisting of ethylene oxide-propylene oxide block copolymer, alkyl ethers of ethylene oxide-propylene oxide block copolymer, alkyl polyglycoside, and combinations thereof.
... |
| Use of a lactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity | 20090275525 | 20091105 |
| The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.
... |
| Reversible natural product glycosyltransferase-catalyzed reactions, compounds and related methods | 20090275485 | 20091105 |
| The present invention relates to methods of use of glycosyltransferases and related novel compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomolecules and numerous one-pot reactions for generation of new biomolecules having varied backbones such as enediynes, vancomycins, bleomycins, anthracyclines, macrolides, pluramycins, aureolic acids, indolocarbazoles, aminglycosides, glycopeptides, polyenes, coumarins, benzoisochromanequinones, calicheamicins, erythromycin, avermectins, ivermectins, angucyclines, cardiac glycosides, steroids or flavinoids. In preferred embodiments, the invention specifically relates to biosynthesis of anticancer (the enediyne calicheamicin, CLM), anthelmintic agents (the macrolides avermectin, ivermectin and erythromycin) and antibiotic (the glycopeptide vancomycin, VCM) natural product-based drugs developed by reversible, bidirectional glycosyltransferase-catalyzed reactions.
... |
| Use of an alkyl glycoside or of a mixture of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and methods of cosmetic care using said compositions | 20090274760 | 20091105 |
| The present invention relates to a novel use of alkyl glycosides and of mixtures of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and to methods of cosmetic care using the said compositions.
... |
| Cosmetic use of a c-glycoside derivative in combination with ascorbic acid | 20090274638 | 20091105 |
| The present invention relates to a cosmetic use of a synergistic combination of at least one C-glycoside derivative with at least ascorbic acid, or one of its derivatives or analogs, for preventively or curatively treating the signs of aging of body or facial skin, irrespective of whether they are chronobiological or photoinduced.
... |
| Use of a lactose-derived c-glycoside compound as an agent for activating and regulating cutaneous immunity | 20090275525 | 20091105 |
| The present invention relates to novel lactose-derived compounds of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses.
... |
| Reversible natural product glycosyltransferase-catalyzed reactions, compounds and related methods | 20090275485 | 20091105 |
| The present invention relates to methods of use of glycosyltransferases and related novel compounds. The invention exploits the reversibility of glycosyltransferases to generate new sugars, unnatural biomolecules and numerous one-pot reactions for generation of new biomolecules having varied backbones such as enediynes, vancomycins, bleomycins, anthracyclines, macrolides, pluramycins, aureolic acids, indolocarbazoles, aminglycosides, glycopeptides, polyenes, coumarins, benzoisochromanequinones, calicheamicins, erythromycin, avermectins, ivermectins, angucyclines, cardiac glycosides, steroids or flavinoids. In preferred embodiments, the invention specifically relates to biosynthesis of anticancer (the enediyne calicheamicin, CLM), anthelmintic agents (the macrolides avermectin, ivermectin and erythromycin) and antibiotic (the glycopeptide vancomycin, VCM) natural product-based drugs developed by reversible, bidirectional glycosyltransferase-catalyzed reactions.
... |
| Use of an alkyl glycoside or of a mixture of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and methods of cosmetic care using said compositions | 20090274760 | 20091105 |
| The present invention relates to a novel use of alkyl glycosides and of mixtures of alkyl glycosides having anti-ageing and/or calming properties as active agents in cosmetic compositions, and to methods of cosmetic care using the said compositions.
... |
| Cosmetic use of a c-glycoside derivative in combination with ascorbic acid | 20090274638 | 20091105 |
| The present invention relates to a cosmetic use of a synergistic combination of at least one C-glycoside derivative with at least ascorbic acid, or one of its derivatives or analogs, for preventively or curatively treating the signs of aging of body or facial skin, irrespective of whether they are chronobiological or photoinduced.
... |
| Process of making hoodia plant extract with improved flavor | 20090263510 | 20091022 |
| Processes of making extracts of Hoodia plant containing steroidal glycosides which have improved flavor, by virtue of reduced Levels of discovered negative flavor compounds.
... |
| Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof | 20090263512 | 20091022 |
| This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder. This invention provides compounds comprising at least one sugar, a triterpene, such as... |
| Compositions and methods for antibiotic potentiation and drug discovery | 20090264342 | 20091022 |
| The present invention provides methods for identifying target genes whose partial or complete functional inactivation potentiates the activity of an antibiotic agent, e.g., a quinolone antibiotic. The invention further provides methods for identifying agents that modulate expression of target genes or that modulate activity of expression products of target genes. Agents identified according to various methods of the invention potentiate the activity of antibiotics such as quinolones, aminoglycosides, peptide antibiotics and β-lactams. Also provided are agents that suppress and/or retard resistance to antibiotics. The inventive methods provide potentiating agents and compositions comprising potentiating agents and antibiotics. Such agents and compositions can be used for inhibiting growth or survival of a microbial cell or of treating a subject suffering from or susceptible to a microbial infection.
... |
| Hoodia plant extract with improved flavor | 20090264376 | 20091022 |
| Extracts of Hoodia plant containing steroidal glycosides which have improved flavor, by virtue of reduced levels of discovered negative flavor compounds. Food compositions containing steroidal glycosides with reduced amounts of discovered negative flavor components are also included.
... |
| Anti-neoplastic compositions comprising extracts of black cohosh | 20090264377 | 20091022 |
| A method is provided for treating, preventing or ameliorating neoplasia in a subject. This method includes administering to the subject an amount of actein or an amount of an extract of black cohosh that contains a triterpene glycoside, which amount of the actein or black cohosh is effective to treat, prevent or ameliorate the neoplasia, in combination with an amount of a statin which is effective to treat, prevent, or ameliorate the neoplasia. Related methods for treating, preventing or ameliorating breast cancer, or liver cell neoplasia are also provided. In addition, methods for modulating a cholesterol biosynthesis pathway and a stress response pathway in a subject are provided. These methods include administering to a subject a composition comprising an anti-neoplastic synergistic amount of a statin and... |
| Gas separation membrane | 20090255405 | 20091015 |
| A membrane for gas separation includes a porous support layer and a separation layer. The separation layer comprises a mixture of one or more saccharide derivatives and one or more homopolymers. The saccharide derivative(s) may have a cyclic structure with five or six ring atoms, or a linear structure, or may include monosaccharide derivatives which are bound via glycoside bonds, and the number of monosaccharides bound in this manner may be 2 to 1,000. A membrane can be produced by preparing a homogeneous solution which comprises a saccharide derivative and a homopolymer in a solvent; and pouring the homogenous solution onto a support layer. The membrane may be used in a gas separation module the operation of which makes use of the membrane.
... |
| Method of improving the ocular tolerance of foaming and/or detergent compositions for skin use | 20090258808 | 20091015 |
| The ocular tolerance of cosmetic, dermocosmetic and dermopharmaceutical compositions is improved by the incorporation therein of an effective amount of a polyol-glycoside or of a mixture of polyol-glycosides of formula (I): R1—O-(G)-H (I) in which: —x represents a decimal number between 1 and 5 and G represents the residue of a reducing sugar, and R1 represents a radical of formula (A) —CH2—(CHOH)n—CH2—OH (A) in which n is an integer equal to 2, 3 or 4, or else R1 represents a radical of formula (B) —(CH2—CHOH—CH2—O)m—H (B) in which m is an integer equal to 1, 2 or 3. The invention also relates to new concentrates which contain compounds of formula (I), foaming and/or detergent surfactants and topically acceptable solvents, and also to processes for preparing them.
... |
| Therapeutic use of methionine to reduce the toxicity of aminoglycoside antibiotics | 20090247479 | 20091001 |
| Methods of preventing or reducing ototoxicity in patients undergoing treatment with therapeutically effective amounts of aminoglycoside antibiotics are provided. The methods comprise administering an effective amount of an otoprotective agent comprising methionine or a methionine-like moiety to said patient prior to, simultaneously with, or subsequently to administration of the aminoglycoside antibiotic. Combinations of these time periods can also be employed.
... |
| Novel sweetener compositions and methods of use | 20080317901 | 20081225 |
| The subject invention provides natural low glycemic sweeteners that are palatable and do not contain high glycemic, insulin-stimulating ingredients. In one embodiment, the subject invention provides a novel nutritive-sweetener/carbohydrate comprising kiwi fruit, a glycoside and a carbohydrate. Preferably, the glycoside is a fruit glycoside and the carbohydrate is fructose. In another embodiment, the subject invention provides a novel sweetener/carbohydrate composition comprising caffeine, chromium, and TRUTINA DULCEM. The sweetener/carbohydrate compositions of the subject invention are acceptable for use by persons desiring to avoid high glycemic, insulin-stimulating sugars and sweeteners. More specifically, these compositions are acceptable for use by diabetics and hypoglycemics.
... |
| Removal of contaminants from water using sugar based surfactant enhanced ultrafiltration | 20080308495 | 20081218 |
| Embodiments of the present invention are directed to a process for removal of an at least slightly water-soluble organic compound from an organic-contaminated water solution to provide a purified water solution, including: adding a surfactant to the organic-contaminated water solution in sufficient quantity to achieve at least a critical micellar concentration of the surfactant in the organic-contaminated water solution, wherein the surfactant comprises an alkylglycoside, to provide a micellar water solution comprising micelles comprising the surfactant and the organic compound; contacting an ultrafiltration membrane with the micellar water solution under pressure and temperature conditions sufficient for liquid flow through the ultrafiltration membrane to take place; and collecting liquid permeating the ultrafiltration membrane to provide the purified water solution.
... |
| Cosmetic compositions | 20080305193 | 20081211 |
| A cosmetic composition suitable for topical application to human or animal skin comprising an effective amount of active ingredient dispersed in an acceptable cosmetic base or carrier, wherein the active ingredient comprises a mixture of an amino acid, a low glycemic glycoside and a Vitamin, wherein the amino acid is L-arginine, and wherein the low glycemic glycoside is derived from kiwi fruit.
... |
| Absorption enhancers for drug administration | 20080299079 | 20081204 |
| A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
... |
| Antibacterial 1,4,5-substituted aminoglycoside analogs | 20080300199 | 20081204 |
| The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
... |
| Linkable lewis x analogs | 20080300220 | 20081204 |
| Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.
... |
| Method for the production of multimetal cyanide compounds | 20080300376 | 20081204 |
| M4 is an alkali metal ion or an ammonium ion (NH4+) or an alkylammonium ion (R4N+, R3NH+, R2NH2+, RNH3+ where R═C1-C20-alkyl).
... |
| High-purity rebaudioside a and method of extracting same | 20080300402 | 20081204 |
| A process for recovering Rebaudioside A from Stevia rebaudiana Bertoni plants is provided and includes the steps of sequentially extracting plant material with a first solvent to obtain a first extract, filtering the first extract and passing the first extract through a polar resin to obtain a filtrate, and purifying the filtrate to obtain a crystalline-containing material. With further purification, a product containing over 99% Rebaudioside A is obtained. The present invention is also directed toward a method of purifying stevia glycosides to obtain purified Rebaudioside A. In one embodiment, the method includes silica gel column chromatography using an solvent comprising ethyl acetate and ethanol.
... |
| Lignan glycosidase and utilization of the same | 20080293099 | 20081127 |
| The present invention provides an enzyme having the lignan glycosidation activity by identifying the enzyme that is involved in the production of lignan glycosides, identifying the amino acid sequence of the enzyme polypeptide and the base sequence for a polynucleotide encoding the polypeptide, and based on the information of these sequences, preparing the transformants capable of producing the lignan glycosides.
... |
| Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents | 20080293649 | 20081127 |
| The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
... |
| Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate | 20080293724 | 20081127 |
| The invention provides methods for (a) treating decompensated heart failure; (b) treating compensated heart failure; (c) treating renovascular diseases and (d) treating end-stage renal diseases in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of an angiotensin converting enzyme inhibitor, a β-adrenergic antagonist, an angiotensin II antagonist, an aldosterone antagonist, a cardiac glycoside (digitalis) and a diuretic compound or a combination of two or more thereof. The hydralazine compound may be hydralazine hydrochloride.
... |
| Breast cancer-resistant protein inhibitor | 20080287374 | 20081120 |
| and glycosides, esters, or salts thereof; and an anticancer agent containing the BCRP-inhibitor together with an anticancer agent available as the substrate of BCRP.
... |
| Manufacturing method of kaempferol | 20080280335 | 20081113 |
| Disclosed is a kaempferol preparing method comprising isolating kaempferol from kaempferol glucosides using an acid, a base, an enzyme or a microbe producing the enzyme. More specifically, the method comprises obtaining a plant extract containing kaempferol glycosides from a plant using water or an organic solvent; and hydrolyzing the plant extract using an acid, a base, an enzyme or a microbe producing the enzyme to isolate kaempferol. The kaempferol glycosides comprise camelliaside A or camelliaside B. The plant extract is derived from a seed or leaf of green tea. When using the method of the invention, it is possible to mass-produce kaempferol, which is one of main physiological activating ingredients, from a plant, particularly a seed or leaf of green tea.
... |
| Novel glycopolymers, uses thereof, and monomers useful for preparation thereof | 20080281064 | 20081113 |
| Novel glycopolymers, uses thereof, and monomers useful for preparation thereof are provided. Methods for preparing novel monomers and glycopolymers are also provided. An exemplary polymer can include glycoside containing units and cationic or potentially cationic units.
... |
| Chemical composition useful as corrosion inhibitor | 20080272342 | 20081106 |
| The present invention relates to a chemical composition comprising (a) a glycoside component A comprising at least one glycoside of the formula R(OG)x wherein R is an aliphatic hydrocarbon radical having 1 to 25 carbon atoms or is a radical of formula R1(OR2)m which does not have more than 25 carbon atoms and wherein n=0 to 24 and R1 and R2 are aliphatic hydrocarbon radicals; G is the residue of a saccharide moiety selected from the group consisting of fructose, glucose, mannose, galactose, talose, gulose, allose, altrose, idose, arabinose, xylose, lyxose, ribose and alkoxylated derivatives thereof; and x is 1 to 30; (b) an aspartate component B comprising at least one polymerisation product of aspartic acid, optionally in form of a copolymerisate with fatty acids, polybasic... |
| Flavonoid concentrates | 20080274519 | 20081106 |
| (ii) adjusting the pH to render the flavonoid aglycone relatively insoluble and forming a concentrate containing the same.
... |
| Stabilizing alkylglycoside compositions and methods thereof | 20080268032 | 20081030 |
| The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
... |
| Synthesis of inhibitors of p90rsk | 20080269144 | 20081030 |
| The synthesis of the naturally occurring kaempferol glycoside SLO1O1-1, as well as analogs thereof, has been accomplished, as has its biochemical evaluation. SLO1O1-1 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthetic scheme of the invention verified the structural assignment of the natural SLO1O1-1 product and has provided access to material sufficient for detailed biological evaluation.
... |
| Cosmetic compositions comprising at least one non-ionic surfactant and at least one vinylamide/vinylamine copolymer and methods of use thereof | 20080260666 | 20081023 |
| and a method for treating keratinous substances using said composition.
... |
| Method of obtaining cyanogenic glycoside and related glycosides, as well as genin and sapogenins derivatives of plants of the family sapotaceae for the preparation of cosmetics and dermatological compositions | 20080261291 | 20081023 |
| Procedure for the obtaining of genin and sapogenins extracts by enzymatic hydrolysis of kernels derived of the family Sapotaceae, genus Calocarpum, Chrysophyllum and Lucuma. The enzymes that catalyzes the hydrolysis are exogenous β-glucosidases, of vegetable or microbial origin. The process uses mainly diverse kernel (seeds removed of the endocarp) derived but can also use the cyanogenic glycoside, lucumin and the related similar glycosides directly. It is also object of protection the process for the obtaining of these glycosides, starting of those kernels derived and the usage of these in the obtaining of genin and sapogenins and its uses in cosmetic and dermatologic compositions. The genin and sapogenins extracts are the main products used with these basic similar aims. The obtained genin extract are used in topical... |
| Testosterone generating and metabolizing enhancer | 20080261896 | 20081023 |
| A testosterone generating and metabolizing enhancer is proposed in the invention, which increases concentrations of testosterone in both seminal vesicle and bloodstream, and may further promote the gene expression of metabolizing testosterone into 5α-reductase of dihydrotestosterone. The testosterone generating and metabolizing enhancer of the invention is characterized in that an effective component thereof may be phenylethanoid glycosides; said phenylethanoid glycosides may comprise at least one of echinacoside and acteoside, or may comprise both echinacoside and acteoside, more preferably. The testosterone generating and metabolizing enhancer of the invention may be applied in medicines, substances for external uses on skin, and foods and beverages for mammals (including humans); as well as an animal feed for mammals.
... |
| Glycosides and salts thereof | 20080249165 | 20081009 |
| The invention relates to new polysulfated glycosides of formula (I), the salts thereof formed with alkali metals or alkaline-earth metals, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.
... |
| Fused protein composition | 20080241884 | 20081002 |
| The present invention provides a fusion protein composition comprising a fusion protein molecule of an antibody Fc region having complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant producing the fusion protein composition; a process for producing the fusion protein composition; and a medicament comprising the fusion protein composition.
... |
| Benzylic glycoside derivatives and methods of use | 20080242596 | 20081002 |
| Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
... |
| Wrinkle-diminishing agent | 20080242849 | 20081002 |
| An antiwrinkle agent which is highly effective in alleviating wrinkles caused by the photoaging. The present invention relates to an antiwrinkle agent comprising an eugenyl glycoside.
... |
| Process for producing flavone c glycoside derivatives | 20080242855 | 20081002 |
| It is intended to provide a process for efficiently producing a flavone C glycoside derivative represented by the formula (1) which is an antiallergic substance or its salt, or a flavone C glycoside derivative represented by the formula (4) or its salt. According to this process, the flavone C glycoside derivative represented by the formula (1) or its salt and the flavone C glycoside derivative represented by the formula (4) can be easily and efficiently synthesized by using isovitexine and vitexine contained in herbs and so on as the starting materials.
... |
| Process for improving the sensory properties of fabrics | 20080230736 | 20080925 |
| The invention describes a process for improving the sensory properties of fabrics. The fabrics are treated with a water-based preparation which contains alkyl oligoglycosides in combination with mixtures of mono- and diesters of saturated and unsaturated C16-22 fatty acids with diol and polyols, for example as a spray or in the form of a dryer sheet. The compositions may additionally contain auxiliaries and additives, preferably thickeners, such as in particular polymeric thickeners.
... |
| Immunogenic glycopeptides, screening, preparation and uses | 20080233599 | 20080925 |
| The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them. Said glycopeptides are selected in the group consisting of: a1) glycopeptides essentially consisting of a glycosylated T epitope, comprising 14 to 25 amino acids, among which at least a neutral amino acid is bound to a di- or to a trisaccharide (glycoside linkage) and at least 15% among said amino acids are proline, one of the proline being located in position −1 to −4, relative to the position of said neutral amino acid, which glycopeptides are: exhibited by a class II MHC molecule, specifically identified by T CD+4 lymphocytes induced by immunisation with the... |
| Medical composition containing ginseng secondary glycosides, its preparation method and application | 20080234208 | 20080925 |
| Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia.
... |
| Methods and compositions facilitating entry of compounds into cells | 20080226605 | 20080918 |
| Disclosed are methods and compositions for facilitating entry of compounds to cells. In some forms, the compositions comprise one or more aminoglycosides and one or more lipids. The disclosed compositions can also comprise one or more compounds or compositions. It was discovered that the disclosed compositions increase the efficiency of delivery of compounds into cells. The disclosed compositions and methods increase both delivery into cells and the activity of compounds once delivered into cells. For example, the disclosed methods and compositions can be used to deliver nucleic acids to cells and to thereby increase the activity of such nucleic acids delivered to cells. The disclosed compositions can be used to deliver compounds and compositions to cells in vitro, ex vivo and in vivo. Delivery can be,... |
| Stabilizing alkylglycoside compositions and methods thereof | 20070298010 | 20071227 |
| The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.
... |
| Method of producing recombinant aspergillus niger beta-glucosidase and an aroma spreading plant | 20070292930 | 20071220 |
| A polypeptide having β-glucosidase enzymatic activity, a polynucleotide encoding the polypeptide, a nucleic acid constructs carrying the polynucleotide, transformed or infected cells, such as yeast cells, and transgenic organisms expressing the polynucleotide and various uses of the polypeptide, the polynucleotide, cells and/or organisms, including, producing a recombinant polypeptide having the β-glucosidase enzymatic activity, increasing the level of aroma compounds in alcoholic beverages, as well as other fermentation products of plant material, hydrolyzing cellobiose and thus increasing the level of fermentable glucose, increasing the production of alcohol, such as ethanol from plant material, increasing the aroma released from a plant or a plant product, and hydrolysis or transglycosylation of glycosides.
... |
| Process for production of azulene derivatives and intermediates for the synthesis of the same | 20070293690 | 20071220 |
| A process for producing an azulene derivative useful as a Na+-glucose cotransporter inhibitor, which is high in yield, is simple in operation, is low in cost, is suited for environmental protection, and is advantageous industrially, the process being characterized by reducing and deprotecting at least one compound selected from penta-acyl compounds and tetra-acyl compounds or salts thereof to obtain a C-glycoside compound; and a useful intermediate for synthesis of such an azulene derivative, obtained in the course of the above process.
... |
| Polysulfated glycosides and salts thereof | 20070281893 | 20071206 |
| The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.
... |
| Iridoid glycoside composition | 20070275006 | 20071129 |
| The present invention also relates to the method of producing the iridoid glycoside adjuvant and the products utilizing such adjuvants for induction of cellular immunity. The adjuvants may be used alone or with specific antigens. The two antigens used in the study represents HBsAg, a recombinant antigen expressed in Pichia pastoris, and typhoid Vi polysaccharide purified from Salmonella typhi broth. These antigens are studied for their immunogenicity with the adjuvant iridoid glycoside adjuvant
... |
| Grafted polymer comprising a polyorganosiloxane backbone and gylcoside units | 20070276113 | 20071129 |
| The invention relates to a grafted polymer comprising a polyorganosiloxane backbone and gylcoside units. The invention also relates to a method of preparing the polymer and to the use thereof. The invention further relates to an intermediate compound which is derived from a glycoside and which can be used to graft a polyorganosiloxane.
... |
| New pyrazole derivatives and diabetic medicine containing them | 20070270479 | 20071122 |
| The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.
... |
| Cosmetic or pharmaceutical oil-in-water emulsion | 20070265209 | 20071115 |
| A cosmetic or pharmaceutical oil-in-water (o/w) emulsion including an oil phase and a water phase, where at least 40% by weight of the oil phase is a wax component or a mixture of wax components is provided. A cosmetic or pharmaceutical oil-in-water (o/w) emulsion including 15% to 35% by weight of an oil phase which contains 40% to 70% by weight of a mixture of wax components comprising at least one C16-24 fatty alcohol and at least one wax ester of a C12-24 fatty alcohol and a C12-24 fatty acid; 0.5% to 5% by weight of a nonionic alk(en)yl oligoglycoside surfactant; and 50% to 80% by weight water is also provided.
... |
| Administration of c-glycoside compounds for protecting and/or activating gammadeltat lymphocytes | 20070265210 | 20071115 |
| are useful for protecting and/or stimulating the activity and/or the proliferation of gamma-delta T lymphocyte cells (γδT cells), and are advantageously formulated into cosmetic/pharmaceutical compositions suited for promoting skin tissue repair, for re-equilibrating epidermal proliferation and differentiation disorders which appear with lack of sleep, and for improving the appearance of the head of hair and limiting hair loss.
... |
| Administration of c-glycoside compounds for activating and regulating cutaneous immunity | 20070248556 | 20071025 |
| are useful for stimulating the immune system of the skin and/or as immunoregulators, and are advantageously formulated into cosmetic/pharmaceutical compositions suited for preventing and/or limiting cutaneous immune imbalances, notably those resulting from environmental stresses.
... |
| Pharmaceutical preparations comprising corticosteroids and antiinfective agents | 20070248565 | 20071025 |
| The invention consists of a stable preparation of a combination drug, comprising of an anti-inflammatory agent and an anti-infective agent. The anti-inflammatory agent in this invention is a corticosteroid, and the anti-infective agent is a derivative of quinolone, amino-glycoside or their pharmaceutically acceptable salts. The combination drug essentially comprises of i) an anti-inflammatory agent which is a corticosteroid, ii) an anti-infective agent selected from the group comprising of derivatives of quinolone, aminoglycoside and their pharmaceutically acceptable salts; iii) a complexation enhancing polymer; iv) a solubiliser exhibiting an inclusion phenomenon, along with pharmaceutically acceptable excipients with a suitable carrier system.
... |
| Antioxidant material, anti-deterioration agent and food or beverage | 20070244189 | 20071018 |
| An antioxidant material of the present invention contains flavonoid aglycon and vitamin C. The flavonoid aglycon is eriodictyol and/or diosmetin obtained by treatment of a raw material containing flavonoid glycoside derived from lemons, limes, or sudachis to form the aglycones thereof. It is preferred that this antioxidant material be produced through a step of mixing the flavonoid aglycon and the vitamin C after the treatment to form the aglycones. The treatment to form the aglycones is glycosidase treatment using a β-glycosidase derived from a microorganism of the genus Aspergillus or Penicillium multicolor, or microbial fermentative treatment using a microorganism of the genus Aspergillus. An anti-deterioration agent and a food or beverage of the present invention contain the antioxidant material.
... |
| Regulated stop codon readthrough | 20070224635 | 20070927 |
| Methods for screening or selecting cells expressing a polypeptide of interest, e.g. for selecting cells expressing a desired level of a polypeptidé of interest, for evaluating recombinant polypeptide expression in a population of cells, or for selecting cells expressing a polypeptide with a desired binding affinity to a ligand, as well as for producing a polypeptide of interest from a selected cell, where the cells comprise an expression cassette comprising a first polynucleotide encoding the polypeptide of interest, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon, and where the cells are cultured in the presence of a termination suppression agent, in particular... |
| Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections | 20070218013 | 20070920 |
| A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.
... |
| Emulsifiers for drilling fluids | 20070219097 | 20070920 |
| The invention relates to use of surfactant mixtures in drilling fluids, the mixtures are produced by reacting an aqueous solution of at least one alkyl oligoglycoside and/or alkenyl oligoglycoside with an omega haloacid, or its salts or esters in the presence of an alkali. The mixtures are suitable for use as emulsifiers for invert drilling-fluid systems and improve the filtration characteristics of the systems.
... |
| Emulsifiers for drilling fluids | 20070219098 | 20070920 |
| The invention relates to the use of surfactant mixtures containing alkyl oligoglycosides and alkenyl oligoglycosides (APG) of formula (1), RO-[G]p, in which R represents an alkyl and/or alkenyl radical comprising between 4 and 22 carbon atoms, G represents a sugar radical comprising 5 or 6 carbon atoms and p represents numbers from 1 to 10, mixed with free fatty acids comprising between 6 and 22 C atoms. Preferably, said mixtures are suitable for use as emulsifiers for invert drilling-fluid systems.
... |
| Composition comprising a diuretic and/or cardiac glycosed for the treatment of dna viral infections of the eye | 20070219142 | 20070920 |
| DNA viral infections of the eye are treated or prevented by the application of a composition comprising a diuretic and/or a cardiac glycoside dissolved in a water/ethanol solution wherein the level of the ethanol is adjusted to be acceptable to the eye.
... |
| Natural agent for treatment of gastrointestinal toxicity, associated symptoms and ulcers | 20070213281 | 20070913 |
| The present invention relates to identification of Oroxylum indicum, Indian medicinal plant as a rich source for flavanoid compounds. Mucoprotective and antigastric ulcer properties in the flavone class of compounds isolated therefrom have been identified along with a flavanoids mixture in substantial yields from hexane and acetone extracts. The hexane extract was fractionated, purified and the compounds identified as Oroxylin A, Chrysin and Baicalein. The acetone extract was purified and the compounds obtained identified as methoxy chrysin, Oroxyloside methyl ester and chrysin-7-O-methyl glycoside.
... |
| Glycerol carbonate glycoside | 20070213517 | 20070913 |
| wherein G and n have the same meanings as defined above, by deprotecting the glycerol carbonate glycoside represented by formula (1).
... |
| Compounds and methods for treating fly ash | 20070204763 | 20070906 |
| A compound is provided for treating fly ash and includes a(n) amphoteric, alkyl polyglycoside, ester, derivative of triglyceride, fatty alcohol, alkoxylated fatty alcohol, alkoxylated polyhydric alcohol, and mixtures thereof, wherein the treated fly ash is incorporated into a cement admixture, and is effective in blocking absorptive carbon. A method for treating fly ash in a cementitious mixture including treating with an amphoteric, alkyl polyglycoside, ester, derivative of triglyceride, a fatty alcohol, an alkoxylated fatty alcohol, an alkoxylated polyhydric alcohol, and mixtures thereof is provided. A method for reducing the amount of Portland cement in a cementitious mixture including substituting up to forty percent by total weight of the cement in a mixture with an equal amount of fly ash treated with a(n) amphoteric, alkyl polyglycoside, ester,... |
| Compounds and methods for reducing water content in cementitious mixtures | 20070204764 | 20070906 |
| Compounds for reducing water content in cementitious mixtures selected from an amphoteric, an alkyl polyglycoside, an ester, a triglyceride derivative, and mixtures thereof are provided. Methods are also provided for reducing water content in cementitious mixtures.
... |
| Compositions and methods using a cardiac glycoside | 20070207208 | 20070906 |
| A method of treating patients suffering from renal failure and concomitant cardiovascular disease with a low dose of the cardiac glycoside known as digoxin, and novel dosage forms to accomplish the method and to perform other uses.
... |
| Appetite suppressant compositions | 20070207227 | 20070906 |
| An inherently nourishing edible appetite suppressant product comprising a steroidal glycoside, preferably obtainable from plants of the Asclepiadaceae family, the product being in the unit serving, having a weight of from 20 to 600 grams, and having the energy density of from 1.6 to 23 kilojoules per gram of product. A dietary regimen is also disclosed.
... |
| Aminoglycosides as antibiotics | 20070203081 | 20070830 |
| The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminoglycosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).
... |
| Process for preparing an edible composition comprising steroidal glycosides | 20070196436 | 20070823 |
| A process for preparing an edible aqueous dispersion of one or more steroidal glycosides, the edible dispersion comprising one or more steroidal glycoside, and a food product comprising the dispersion, as well as methods of controlling body weight or obesity by ingesting the food product.
... |
| Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof | 20070197623 | 20070823 |
| The invention relates to substituted fluoroglycoside derivatives of pyrazoles of formula (I) as further defined in the specification, to the physiologically compatible salts thereof, to a method for their production, and to their use as antidiabetics.
... |
| Glycopeptides for the treatment of als and other metabolic and autoimmune disorders | 20070185012 | 20070809 |
| New compositions and methods for treating patients suffering from Amyotrophic Lateral Sclerosis (ALS) and other metabolic and autoimmune disorders, which include glycopeptides such as N-acetyl-D-glucosaminyl(β1-4)-N-Acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and peptide analog-L-alanyl-D-glutamic acid (GMDP-A) of at least 98% purity administered either alone, or in combination with a flavone such as luteolin and/or an isoflavone such as genistein, optionally in combination with a flavonol glycoside such as isoquercitrin or rutin. The high purity glycopeptides have a decreased amount immunogenic impurities and demonstrate a synergistic effect when combined with luteolin and/or genistein in presence of isoquercitrin.
... |
| Glycoside prodrug of 5- aminosalicylic acid | 20070173461 | 20070726 |
| The compound of the present invention can be efficiently delivered to the large intestine of the site of action, and is degraded by the intestinal bacterial flora, whereby 5-ASA as the active ingredient can be produced in the large intestine.
... |
| Synthesis of core sugar chain structure of aspargine-linked glycoprotein | 20070166783 | 20070719 |
| It is intended to chemically synthesize the trisaccharide moiety at the reducing end in the core sugar chain structure of an asparagine-linked glycoprotein. By using a highly inexpensive natural polysaccharide having a mannoseβ-1,4-bond as the starting material, a β-1,4-glycoside bond of mannose is formed.
... |
| Nanoemulsions | 20070160651 | 20070712 |
| A nanoemulsion with a mean particle diameter of 20 to 250 nm including 5 to 50% by weight of at least one alkyl and/or alkenyl oligoglycoside carboxylic acid salt corresponding to formula (I): R1O[G]pO[(CH2)mCOO−X+]n wherein R1 is an alkyl and/or alkenyl group containing 4-22 carbon atoms, G is a sugar unit containing 5 or 6 carbon atoms, p is a number of 1-10, m is a number of 1-5, n is a number of 1-5 and X represents alkali metal, alkaline earth metal, ammonium, alkanolammonium, alkyl ammonium or glucammonium; 10 to 50% by weight of an oil component; and 0 to 15% by weight of mono- and/or polyhydric alcohols containing 1 to 4 carbon atoms, and an article or formulation containing the nanoemulsion are provided.
... |
| Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof | 20060293252 | 20061228 |
| in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for their preparation are disclosed. The compounds are suitable, for example, as antidiabetics.
... |
| Pharmaceutical composition useful for the treatment of hepatocellular carcinoma | 20060280817 | 20061214 |
| The present invention relates to anticancer activity against hepatocellular carcinoma of an extract and fraction isolated from flowers of Butea monosperma. Particularly, this invention relates to anticancer activity against hepatocellular carcinoma of a composition containing markered flavonoid glycosides such as butrin and isobutrin in the range of 2 to 9% by weight, isolated from the flowers of Butea monosperma by extracting the flowers with polar solvent like ethanol, methanol, aqueous ethanol or water, removing fatty non-polar constituents by triturating the extract with solvents such as ethylene chloride, methylene chloride, chloroform or ethyl acetate, suspending the residue in water, extracting with n-butanol and freeze drying the aqueous part.
... |
| Saponin-decomposing enzyme, gene thereof and large-scale production system for producing soyasapogenol b | 20060275862 | 20061207 |
| The present invention provides a protein having saponin-decomposing activity, more specifically a protein which can decompose a glycoside having soyasapogenol B as an aglycone to produce soyasapogenol B, a polynucleotide encoding such a protein, and a method of producing soyasapogenol B on a large scale using the same. A protein according to the present invention are concerned with (a), (b) or (c), namely (a) a protein comprising an amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 2, 4, and 6; (b) a protein that has at least 50% homology to the protein comprising the amino acid sequence of the sequence described in (a) and having saponin-decomposing activity; or (c) a protein comprising a modified amino acid... |
| Compositions for potentiating glutatthione | 20060257351 | 20061116 |
| A composition for potentiating glutathione, which contains at least one member selected from the group consisting of 2-(3,4-dihydroxyphenyl)ethanol or a glycoside thereof, a plant containing 2-(3,4-dihydroxyphenyl)ethanol or a glycoside thereof, an extract of said plant, a hydrolysate of said plant, and a hydrolysate of the extract of said plant (excluding Olea europaea and an extract thereof), and which further contains at least one member selected from among an S-containing compound that is a supply source of cysteine, a protein that contains cysteine and/or cystine, a yeast that contains cysteine and/or cystine, and a vitamin.
... |
| Plant seed extract composition and process for producing the same | 20060257540 | 20061116 |
| Plant seed extract compositions obtained by washing a defatted plant seed with water, and extracting the resulting washed seed product with an organic solvent and safflower seed extract compositions wherein the weight ratio of the total content of (a) p-coumaroylserotonin, feruloylserotonin, p-coumaroylserotonin glycoside, and feruloylserotonin glycoside to (b) 2-hydroxyarctiin is 1:0.01 to 0.2, are effective for reducing the risk of developing atherosclerosis and diseases caused by atherosclerosis and also exhibit a reduced tendency to cause diarrhea.
... |
| Textile finishing agents | 20060258558 | 20061116 |
| A method for treating fibers, yarns or textiles to improve the sensory effect for a user or weaver of a fabric article. The method treats the fiber, yarns or textiles with an emulsion containing 15-30% by weight of a mixture of waxes having melting points in the range of 35° C. to 60° C. including a lipophilic wax matrix; 10%-20% by weight of emulsifier which are at least one of alkyl or alkenyl oligoglycosides or alkyl ether sulfates, 1%-10% by weight of a crystal regulator which can be partial esters of C12-22 fatty acids with at least one of glycerol, polyglycerol and sorbitan. The mean particle size of the wax crystals is not greater than 6 μm. The emulsion includes water and auxiliaries and additives.
... |
| Attenuation of disorders by aminoglycosides | 20060247187 | 20061102 |
| The present invention provides a method of attenuating side effects caused by aminoglycosides by administering aminoguanidine either before or during the treatment with the aminoglycoside. The invention also provides compositions and kits for use in the treatment of infections that use aminoglycosides that can cause side effects such as nephrotoxicity and ototoxicity.
... |
| Process for producing fine self-aggregates | 20060240527 | 20061026 |
| (in the formula X1 represents a glycosyl group or an oligosaccharide group having two to twenty-nine monosaccharides and R is as defined above), 2) a monosaccharide or its derivative and 3) a glycotransferase or glycolytic enzyme are reacted in water.
... |
| Alkyl-glycoside enhanced vaccination | 20060233761 | 20061019 |
| Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject.
... |
| Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | 20060233896 | 20061019 |
| The body of a herbaceous plant, Cistanche tubulosa (Schenk.) Wight, is used to make a medicinal preparation containing phenylethanoid glycosides and comprising 10-70% of echinacoside by weigh of the preparation and 1-40% of acteoside by weight of the preparation. The medicinal preparation is used as an active ingredient of medicinal composition for use in prevention of senile dementia, and inhibition of aggregation of blood platelets.
... |
| Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders | 20060234955 | 20061019 |
| A method of inhibiting the secretion of IL-8 and other pro-inflammatory cytokines from cells secreting elevated levels of these compounds is provided. The method includes contacting the cell with a composition comprising a cardiac glycoside such as oleandrin. The cardiac glycoside can be used to treat cystic fibrosis and other IL-8 dependent disorders by lowering levels of spontaneously secreted IL-8 and other pro-inflammatory cytokines. Oleandrin was found to suppress the secretion of IL-8 from cultured CF lung epithelial cells in the nanomolar concentration range. Structure-activity relationships (SARs) for cardiac glycosides are also elucidated.
... |
| Adiponectin expression promoter | 20060234957 | 20061019 |
| To prevent or alleviate various pathologies caused by lifestyle-related diseases, etc., the present invention provides a substance having an effect of promoting the expression and elevating the expression level of adiponectin, and applications thereof. An adiponectin expression promoting agent containing, as an active ingredient, at least one cyanidin compound selected from the group consisting of cyanidin and cyanidin glycosides can be applied to pharmaceutical or food compositions for use in applications in which the pharmacological effects of adiponectin are utilized.
... |
| Compositions containing piperacillin and tazobactam useful for injection | 20060234995 | 20061019 |
| An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution.
... |
| Cardiac glycoside resistant non-immunogenic selection marker | 20060228343 | 20061012 |
| A recombinant Na+, K+-ATPase α1-subunit protein resistant to cardiac gIycosides, e.g. oubain, is disclosed, as well as methods for its production and use. The resistance to cardiac glycosides are obtained b y alterations in the region situated between and including the amino acids 65-133. Such recombinant protein and nucleic acid constructs expressing the same are useful as selection markers in gene therapy and research applications.
... |
| Substituted fused heterocyclic c-glycosides | 20060229260 | 20061012 |
| This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
... |
| Process for producing glycoprotein composition | 20060223147 | 20061005 |
| The present invention relates to a cell into which an RNA capable of suppressing the function of an enzyme catalyzing a reaction which converts GDP-mannose into GDP-4-keto,6-deoxy-GDP-mannose is introduced; a process for producing a glycoprotein using the cell; a cell into which an RNA capable of suppressing the function of an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in the complex type N-glycoside-linked sugar chain, and an RNA capable of suppressing the function of an enzyme relating to synthesis of an intracellular sugar nucleotide, GDP-fucose, or an RNA capable of suppressing the function of a protein relating to transport of an intracellular sugar nucleotide, GDP-fucose, to the Golgi... |
| C-glycoside compounds for stimulating the synthesis of glycosaminoglycans | 20060223763 | 20061005 |
| C-glycoside compounds are suited for stimulating the synthesis of glycosaminoglycans containing a D-glucosamine and/or N-acetyl-D-glucosamine residue, advantageously hyaluronic acid, and/or proteoglycans, advantageously proteoglycans containing hyaluronic acid, by fibroblasts and/or keratinocytes.
... |
| Method for inhibiting and/or treating vaginal infection | 20060223765 | 20061005 |
| A method for inhibiting and/or treating infection in a vagina is provided. The method comprises exposing one or more microbes to a treatment composition. The microbes are selected from the group consisting of Gardnerella, Candida, and Trichomonas, and the treatment composition comprises an effective amount of a saccharide-based nonionic surfactant. For example, in one embodiment, the saccharide-based nonionic surfactant is an alkyl glycoside.
... |
| Process for producing aglycon and flavor-improved food containing the aglycon by diglycosidase, and converting agent to be used in the process | 20060216281 | 20060928 |
| A physiologically active substance of aglycon type, in particular, aglycon isoflavone, can be efficiently produced, without resort to any acid/alkali treatment or fermentation and substantially without changing the physical properties of a material, by treating the material with a sufficient amount of diglycosidase for a sufficient period of time at an appropriate temperature and pH so that a physiologically active substance of glycoside type contained in the material can be converted into the physiologically active substance of aglycon type. Moreover, by using diglycosidase and/or a specific enzyme preparation, the aglycon content in a protein or protein-containing food can be increased and the flavor thereof can be improved.
... |
| Anti-obesity agent | 20060210659 | 20060921 |
| The object of the present invention is to provide an active substance which has an anti-obesity effect such as a triglyceride lowering activity, a cholesterol lowering activity and the like. The present invention provides a blood triglyceride lowering agent, a cholesterol lowering agent, a body fat storage suppressive agent, an anti-obesity agent and an antilipemic agent, characterized in that each of said agents comprises a cycloartane-type triterpene or glycoside thereof. Moreover, the present invention provides the use of a Black cohosh plant in order to prepare said agents. Further, the present invention provides a beverage, food and quasi-drug comprising said agents.
... |
| Inhibitors of aminoglycoside 6'-n-acetyltransferases, compositions and uses thereof | 20060211634 | 20060921 |
| R7 is selected from the group consisting of OH, OMe, OEt OPr, O-iPr, O-tBu and
... |
| Method for separating sugar from compound having glycoside bond, sugar separation system, sugar separation agent kit, standardized sample for sugar separation and assessment system | 20060211849 | 20060921 |
| In an in-flow chemical reaction system (A) of the present invention, a sample solution (1) containing glycoprotein is injected into a reaction tube (7) in which an alkaline solution continuously flows. When a mixed solution of the sample solution and the alkaline solution reach a thermostat bath (6), reaction for cleaving a glycoside linkage takes place, thereby separating a carbohydrate chain from glycoprotein. From the solution containing the carbohydrate chain, alkali is removed by using an ion-exchange column (12), so that a fraction of a carbohydrate chain (14) is collected into a sample tube (13). In the in-flow chemical reaction system (A), reaction takes place in minutes, so that reaction time is significantly reduced compared to a conventional method. Thus, a glycoside linkage is readily cleaved... |
| Topical and oral formulations of cardiac glycosides for treating skin diseases | 20060205679 | 20060914 |
| The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.
... |
| Method of preparing 4-r-substituted 4-demethoxydaunorubicin | 20060205684 | 20060914 |
| A method of synthesizing 4-R-substituted anthracyclines and their corresponding salts from 4-demethyldaunorubicin includes the steps of treating 4-demethyldaunorubicin with a sulfonylating agent to form 4-demethyl-4-sulfonyl-R3-daunorubicin. 4-Demethyl-4-R3-sulfonyl-daunorubicin is then subject to a reducing agent in the presence of a transition metal catalyst in a temperature range of about 30° C. to about 100° C. in a polar aprotic solvent in an inert atmosphere. Protected 4-demethoxy-4-R-daunomycin then undergoes hydrolysis in a basic solution to form the 4-R-substituted anthracyclines. The novel method lacks the step of forming a stereospecific glycoside bond between aglycone and aminoglycoside. The method also increases the yield of the final product up to 30 to 40%.
... |
| Glycopeptide compositions | 20060198786 | 20060907 |
| The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects. The glycopeptides may be made by combining a glycoside and a... |
| Thermostable enzyme compositions | 20060193843 | 20060831 |
| The present invention relates to a composition comprising at least two thermostable enzymes selected from the group consisting of endoglucanase, xylanase, phytase, protease, galactanase, mannanase, dextranase, and alpha-galactosidase. The thermostable enzymes have a melting temperature, Tm, of at least 70° C. Preferred compositions comprise a xylanase of glycoside hydrolase family 11, and an endoglucanase which is homologous to a thermostable glycoside hydrolase family 5 endoglucanase derived from Thermoascus aurantiacus. Preferred xylanases are derived from Aspergillus, Bacillus, Humicola, Thermomyces and Trichoderma. The composition is particularly useful for animal feed purposes. Optional additional components are vitamins, minerals, and anti-microbial peptides.
... |
| Additive for food and beverage, pharmaceutical composition, glut4 translocator, and method for translocating glut4 | 20060193895 | 20060831 |
| wherein R1 to R4 are each a glycoside group, a hydroxyl group, or a hydrogen atom, R5 is a carboxyl group and R6 to R8 are each a methyl group or a hydrogen atom.
... |
| Glycoside-containing liposome | 20060193903 | 20060831 |
| A drug product which can maximize the effect of a cholestanol glycoside useful as an anticancer agent. The present invention provides a liposomal composition containing a glycoside exhibiting antitumor activity, a phospholipid, and a positive-charge-providing substance; the glycoside being composed of GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- as a sugar moiety, and a hydrophobic compound capable of forming a liposome.
... |
| Low foaming formulation of gylphosate | 20060172889 | 20060803 |
| A low-foaming herbicidal composition comprises glyphosate and a poly(alkylene oxide)alkanol having the formula R1R2CH—R3—(OR4)n—OH (I) wherein R1 and R2 are methyl or ethyl, R3 is a straight chain alkylene group containing from 5 to 12 carbon atoms, R4 is an alkylene group containing 2 or 3 carbon atoms and n is from 4 to 20. Especially preferred is ethoxylated, propoxylated or mixed alkoxylated/propoxylated iso-tridecyl alcohol wherein the degree of alkoxylation is from 6 to 14, for example iso-tridecyl alcohol having 8 polyethylene oxide units. Preferred compositions additionally contain an alkylglycoside.
... |
| Method for producing alkyl oligoglucoside-and/or alkenyl oligoglucoside carboxylic acid salts | 20060172915 | 20060803 |
| A process for reducing the amount of halocarbons in a mixture containing water and at least one of an alkyl or alkenyl glycoside carboxylic acid. The amount of halocarbon is reduced by heating the mixture at a temperature of 50° C. to 120° C. at a pH of from 10-14. The amount of organomonochloro compounds can be reduced to a range of 5 ppm or less and the amount of organodichloro compounds can be reduced to a range of 30 ppm.
... |
